The treatment of venous thromboembolism with novel oral anticoagulants: Warnings and limitations

Blood Transfusion

Volumn 13, Issue 2, 2015, Pages 178-180

  Prandoni, Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADVANCED CANCER; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOT LYSIS; BODY WEIGHT; BREAST FEEDING; CANCER PATIENT; CANCER PROGNOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; LIFE EXPECTANCY; LONG TERM CARE; META ANALYSIS; OUTPATIENT; PARENTERAL NUTRITION; PATIENT SAFETY; PREGNANT WOMAN; SEVERE RENAL IMPAIRMENT; THROMBECTOMY; ULCER; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; BLOOD; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84927518854     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0002-15     Document Type: Article

References (16)

1. Prandoni P. Venous thromboembolism in 2013: the advent of the novel oral anticoagulants. Nat Rev Cardiol 2014;11:70-2.
2. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75.
3. Cohen AT, Imfeld S, Rider T. Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther 2014;31:473-93.
4. Prandoni P, Barbar S, Vedovetto V, et al. Treatment of venous thromboembolism: the single-drug approach. Clin Pract 2013;10:607-13.
5. Prandoni P, Barbar S, Milan M, et al. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests. Thromb Haemost 2014; DOI 10.1160/TH14-04-0396.
6. Lega JC, Bertoletti L, Gremillet C, et al. Consistency of safety profile of new oral anticoagulants in patients with renal failure. J Thromb Haemost 2014;12:337-43.
7. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEINDVT and PE randomized studies. Thromb J 2013;11:21.
8. Hoffman A, Galle PR. Gastrointestinal disorders and dabigatran. Scand J Gastroenterol 2013;48:9-16.
9. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase the risk of gastrointestinal bleeding - a systematic review and meta-analysis. Ned Tijdschr Geneeskd 2013;145:105-12.
10. Douxfils J, Buckinx F, Mullier F, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014;3:e000515.
11. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18.
12. Dale B, Eikelboom JW, Weitz JI, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 2013;35:295-301.
13. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e419S-94S.
14. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2011;106:868-76.
15. Alotaibi G, Alsaleh K, Wu C, Mcmurtry MS. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. Int Angiol 2014;33:301-8.
16. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708.